{
    "nctId": "NCT04871139",
    "briefTitle": "An Imaging Technology, Contrast-Enhanced Mammography, in Predicting Breast Cancer",
    "officialTitle": "Contrast-Enhanced Mammography (CEM) for the Evaluation and Targeted Biopsy of Suspicious Mammographic Architectural Distortions",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Carcinoma",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Accuracy of contrast-enhanced mammography (CEM)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women with suspicious MADs recommended for a stereotactic biopsy who underwent their diagnostic imaging work-up resulting in a biopsy recommendation at MD Anderson Cancer Center (MDACC) or at an outside facility with a technically acceptable quality of diagnostic mammography, and who are planning to have their biopsy at MDACC\n* Age 25-85 years\n* Willing to participate in the study, undergo an IV placement, able to undergo iodinated contrast injection, and able to provide informed consent\n\nExclusion Criteria:\n\n* Reported history of an allergic reaction to iodinated contrast\n* History of anaphylactic reaction to any substance\n* Renal insufficiency\n* Pregnancy or lactation within 6 months\n* Breast surgery affecting the site of interest within prior 6 months\n* Breast biopsy at the site of interest within the last 2 months",
    "sex": "ALL",
    "minimumAge": "25 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}